Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Jolanda Howe Sells 57,606 Shares

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Jolanda Howe sold 57,606 shares of the stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $44.35, for a total value of $2,554,826.10. Following the completion of the transaction, the senior vice president now directly owns 4,841 shares of the company’s stock, valued at approximately $214,698.35. The trade was a 92.25 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link.

Jolanda Howe also recently made the following trade(s):

• On Monday, February 3rd, Jolanda Howe sold 1,064 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $48.22, for a total value of $51,306.08.
• On Friday, January 24th, Jolanda Howe sold 902 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $47.92, for a total value of $43,223.84.
• On Tuesday, January 7th, Jolanda Howe sold 750 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $42.82, for a total value of $32,115.00.

Mirum Pharmaceuticals Stock Down 1.9 %

NASDAQ MIRM opened at $44.31 on Wednesday. The stock has a fifty day moving average of $47.55 and a 200-day moving average of $43.60. The stock has a market capitalization of $2.17 billion, a P/E ratio of -21.94 and a beta of 1.04. Mirum Pharmaceuticals, Inc. has a 52 week low of $23.14 and a 52 week high of $54.23. The company has a debt-to-equity ratio of 1.33, a quick ratio of 3.15 and a current ratio of 3.34.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its earnings results on Wednesday, February 26th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.22). The firm had revenue of $99.41 million during the quarter, compared to analyst estimates of $96.64 million. Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. On average, equities research analysts forecast that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current year.

Institutional Investors Weigh In On Mirum Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in MIRM. Connor Clark & Lunn Investment Management Ltd. increased its stake in shares of Mirum Pharmaceuticals by 46.9% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 67,375 shares of the company’s stock valued at $2,628,000 after buying an additional 21,526 shares during the period. Intech Investment Management LLC acquired a new stake in shares of Mirum Pharmaceuticals during the third quarter worth $497,000. HealthInvest Partners AB grew its stake in shares of Mirum Pharmaceuticals by 83.9% during the third quarter. HealthInvest Partners AB now owns 138,321 shares of the company’s stock worth $5,395,000 after purchasing an additional 63,121 shares during the period. Charles Schwab Investment Management Inc. grew its stake in shares of Mirum Pharmaceuticals by 5.5% during the third quarter. Charles Schwab Investment Management Inc. now owns 328,161 shares of the company’s stock worth $12,798,000 after purchasing an additional 17,149 shares during the period. Finally, Loomis Sayles & Co. L P acquired a new stake in shares of Mirum Pharmaceuticals during the third quarter worth $19,473,000.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on MIRM shares. HC Wainwright raised their price target on Mirum Pharmaceuticals from $66.00 to $72.00 and gave the company a “buy” rating in a report on Friday, February 28th. Robert W. Baird raised their price target on Mirum Pharmaceuticals from $50.00 to $55.00 and gave the company an “outperform” rating in a report on Thursday, February 27th. Ten analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $58.20.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.